Clinical Trial Update: HER2 and LA/mUC: A Multi-country Chart Review Cohort Study

View source ↗

Summary

A multi-country chart review cohort study evaluating HER2-directed therapy in locally advanced or metastatic urothelial carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)

Snippet

Sponsor: Seagen, a wholly owned subsidiary of Pfizer | Conditions: Urothelial Carcinoma | Status: COMPLETED